Molecular mechanisms and proposed targets for selected anticancer gold compounds

Current Topics in Medicinal Chemistry

Volumn 11, Issue 21, 2011, Pages 2647-2660

  Casini, Angela ^a   Messori, Luigi ^b  

^a EPFL   (Switzerland)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Apoptosis; Cancer; Gold complexes; Mechanism of action; Mitochondria; Protein targets

Indexed keywords

ANTINEOPLASTIC AGENT; AURANOFIN; DITHIOCARBAMIC ACID; GOLD DERIVATIVE; GOLD PORPHYRIN; MITOGEN ACTIVATED PROTEIN KINASE; PORPHYRIN; PROTEIN BCL 2; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL VIABILITY; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOLECULAR MECHANICS; NONHUMAN; OXIDATION; REVIEW;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GOLD; HUMANS; MITOCHONDRIA; MODELS, MOLECULAR; NEOPLASMS; ORGANOGOLD COMPOUNDS; PORPHYRINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS; THIOCARBAMATES; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 80055080734     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798040732     Document Type: Review

References (116)

1. Hartinger, C. G.; Dyson, P. J. Bioorganometallic chemistry-from teaching paradigms to medicinal applications. Chem. Soc. Rev., 2009, 38, 391-401.
2. Reedijk, J. Platinum Anticancer Coordination Compounds: Study of DNA binding inspires new drug design. Eur. J. Inorg. Chem.,2009, 1303-1312.
3. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumour metal compounds: more than theme and variations. Dalton Trans., 2008, 183-194.
4. Aris, S. M.; Farrell, N. P. Towards antitumor active trans-platinum compounds. Eur. J. Inorg. Chem., 2009, 1293-1302.
5. Tiekink, E. R. Anti-cancer potential of gold complexes. Inflammopharmacology,2008, 16, 138-142.
6. Nobili, S.; Mini, E.; Landini, I.; Gabbiani, C.; Casini, A.; Messori, L. Gold Compounds as anticancer agents. chemistry, cellular pharmacology and preclinical studies. Med. Res. Rev., 2009.
7. Shaw, C. F. Gold-based therapeutic agents. Chem. Rev.,1999, 99, 2589-2600.
8. Messori, L.; Marcon, G. Gold complexes as antitumor agents. Metal Ions in Biolgical Systems, Vol 42: Metal Complexes in Tumor Diagnosis and as Anticancer Agents,2004, 42, 385-424.
9. Wang, X. Y.; Guo, Z. J. Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents. Dalton Trans., 2008, 1521-1532.
10. Fricker, S. P. Literature highlights.39. Medicinal chemistry and pharmacology of gold compounds. Transition Metal Chem., 1996, 21, 377-383.
11. Messori, L.; Marcon, G. Gold complexes in the treatment of rheumatoid arthritis. Metal Ions in Biological Systems, Vol 41: Metal Ions and Their Complexes in Medication,2004, 41, 279-304.
12. Bindoli, A.; Rigobello, M. P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev. 2009, 253, 1692-1707.
13. Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev., 2009, 253, 1670-1681.
14. Casini, A.; Hartinger, C.; Gabbiani, C.; Mini, E.; Dyson, P. J.; Keppler, B. K.; Messori, L. Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action. J. Inorg. Biochem., 2008, 102, 564-575.
15. Shaw, C. F. Chrysotherapy: Gold-drug metabolism and immunochemistry. Top. Biol. Inorg. Chem., 1999, 2, 187.
16. Kean, W. F.; Hart, L.; Buchman, W. W. Auranofin. Br. J. Rheumatol., 1997, 36, 560-572.
17. Shaw, C. F. The protein chemistry of antiarthritic gold(I) thiolates and related complexes. Comm. Inorg. Chem., 1989, 8, 233-267.
18. Brown, D. H.; Smith, W. E. The Chemistry of the Gold Drugs Used in the Treatment of Rheumatoid-Arthritis. Chem. Soc. Rev., 1980, 9, 217-240.
19. Shoeib, T.; Atkinson, D. W.; Sharp, B. L. Structural analysis of the anti-arthritic drug Auranofin: Its complexes with cysteine, selenocysteine and their fragmentation products. Inorg. Chim. Acta, 363, 184-192.
20. Roberts, J. R.; Xiao, J.; Schleisman, B.; Parsons, D. J.; Shaw, C. F. Kinetics and mechanism of the reaction between serum albumin and auranofin (and its isopropyl analogue) in vitro. Inorg. Chem., 1996, 35, 424-433.
21. Hill, D. T.; Sutton, B. M.; Sadler, P. J.; Calis, G. H. M.; Trooster, J. M. Oral gold auranofin, a novel anti-arthritic agent, its mossbauer spectrum and x-ray crystal-structure determination. Abs. Papers Am. Chem. Soc., 1980, 179, 16-MEDI.
22. Mohamed A. A.; Bruce, A. E.; Bruce, M. R. Cyclic voltammetry of auranofin. Metal Based Drugs,1999, 6, 233-238.
23. Hernandez Mendez, J.; Sanchez Perez, A.; Delgado Zamarreno, M. Electrochemical behavior and polarographic determination of auranofin. J. Pharm. Sci., 1989, 78, 589-591.
24. Mohamed, A. A.; Chen, J. H.; Bruce, A. E.; Bruce, M. R. M.; Bauer, J. A. K.; Hill, D. T. Formation of a cationic gold(I) complex and disulfide by oxidation of the antiarthritic gold drug auranofin. Inorg. Chem., 2003, 42, 2203-2205.
25. Abdou, H. E.; Mohamed, A. A.; Fackler, J. P.; Burini, A.; Galassi, R.; Lopez-de-Luzuriaga, J. M.; Olmos, M. E. Structures and properties of gold(I) complexes of interest in biochemical applications. Coord. Chem. Rev.,2009, 253, 1661-1669.
26. Weidauer, E.; Yasuda, Y.; Biswal, B. K.; Cherny, M.; James, M. N. G.; Bromme, D. Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S. Biol. Chem., 2007, 388, 331-336.
27. Jeon, K. I.; Byun, M. S.; Jue, D. M. Gold compound auranofin inhibits I kappa B kinase (IKK) by modifying Cys-179 of IKK beta subunit. Exp. Mol. Med., 2003, 35, 61-66.
28. Eisler, R. Gold causes genetically determined autoimmune and immunostimulatory responses in mice. Clin. Exp. Immunol., 2003, 150, 179-188.
29. Havarinasab, S.; Johansson, U.; Pollard, K. M.; Hultman, P. Gold causes genetically determined autoimmune and immunostimulatory responses in mice. Clin. Exp. Immunol., 2007, 150, 179-188.
30. Hashimoto, K.; Whitehurst, C. E.; Matsubara, T.; Hirohata, K.; Lipsky, P. E. Immunomodulatory effects of therapeutic gold compounds gold sodium thiomalate inhibits the activity of t-cell protein-kinase-C. J. Clin. Invest. 1992, 89, 1839-1848.
31. Chircorian, A.; Barrios, A. M. Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I). Bioorg. Med. Chem. Lett., 2004, 14, 5113-5116.
32. Larabee, J. L.; Hocker, J. R.; Hanas, J. S. Mechanisms of aurothiomalate cys2his2 zinc finger interactions. Chem. Res. Toxicol., 2005, 18, 1943-1954.
33. Simon, T. M.; Kunishima, D. H.; Vibert, G. J.; Lorber, A. Cellular antiproliferative action exerted by auranofin. J. Rheumatol., 1979, 6, 91-97.
34. Mirabelli, C. K.; Johnson, R. K.; Hill, D. T.; Faucette, L. F.; Girard, G. R.; Kuo, G. Y.; Sung, C. M.; Crooke, S. T. Correlation of the invitro cytotoxic and invivo antitumor activities of gold(i) coordination-complexes. J. Med. Chem., 1986, 29, 218-223.
35. Sadler, P. J.; Sue, R. E. The chemistry of gold drugs. Metal Based Drugs., 1994, 1, 107-144.
36. Berners-Price, S. J.; Mirabelli, C. K.; Johnson, R. K.; Mattern, M. R.; Mccabe, F. L.; Faucette, L. F.; Sung, C. M.; Mong, S. M.; Sadler, P. J.; Crooke, S. T. Invivo antitumor-activity and invitro cytotoxic properties of bis [1,2-bis(diphenylphosphino)ethane]gold(i) chloride. Cancer Res., 1986, 46, 5486-5493.
37. Bernersprice, S. J.; Girard, G. R.; Hill, D. T.; Sutton, B. M.; Jarrett, P. S.; Faucette, L. F.; Johnson, R. K.; Mirabelli, C. K.; Sadler, P. J. Cytotoxicity and antitumor-activity of some tetrahedral bis(diphosphino)gold(i) chelates. J. Med. Chem., 1990, 33, 1386-1392.
38. Hoke, G. D.; Macia, R. A.; Meunier, P. C.; Bugelski, P. J.; Mirabelli, C. K.; Rush, G. F.; Matthews, W. D. Invivo and invitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit. Toxicol. Appl. Pharmacol., 1989, 100, 293-306.
39. McKeage, M. J.; Berners-Price, S. J.; Galettis, P.; Bowen, R. J.; Brouwer, W.; Ding, L.; Zhuang, L.; Baguley, B. C. Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemother. Pharmacol., 2000, 46, 343-350.
40. Liu, J. J.; Galettis, P.; Farr, A.; Maharaj, L.; Samarasinha, H.; McGechan, A. C.; Baguley, B. C.; Bowen, R. J.; Berners-Price, S. J.; McKeage, M. J. In vitro antiturnour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. J. Inorg. Biochem. 2008, 102, 303-310.
41. ] Papathanasiou, P.; Salem, G.; Waring, P.; Willis, A. C. Synthesis of gold(I), silver(I) and copper(I) complexes containing substituted (2-aminophenyl)phosphines. Molecular structures of [AuI(2-H2NC6H4PPh2)], [AuI{(+/-)-2-H2NC6H4PMePh}] and (+/-) [Cu(2-H2NC6H4PPh2)(2)]PF6. J. Chem. Soc. Dalton Trans., 1997, 3435-3443.
42. McKeage, M. J.; Papathanasiou, P.; Salem, G.; Sjaarda, A.; Swiegers, G. F.; Waring, P.; Wild, S. B. Antitumor activity of gold(I), silver(I) and copper(I) complexes containing chiral tertiary phosphines. Metal. Based Drugs, 1998, 5, 217-223.
43. Arizti, M. P.; Garciaorad, A.; Sommer, F.; Silvestro, L.; Massiot, P.; Chevallier, P.; Gutierrezzorrilla, J. M.; Colacio, E.; Depancorbo, M. M.; Tapiero, H. Intracellular accumulation and cytotoxic effect of (8-Thiotheophyllinate) (Triphenylphosphine) Gold(I) in friend-leukemia cells. Anticancer Res.,1991, 11, 625-628.
44. Garcia-Orad, A.; Arizti, M. P.; Sommer, F.; Silvestro, L.; Massiot, P.; Chevallier, P.; Gutierrez-Zorrilla, J. M.; Colacio, E.; Martinez de Pancorbo, M.; Tapiero, H. The (8-thiotheophyllinate) (triphenylphosphine) gold (I), (tTAuP): A new gold complex as an anticancer agent. Biomed. Pharmacother., 1993, 47.
45. Webster, L. K.; Rainone, S.; Horn, E.; Tiekink, E. R. Anti-tumor activity, in vitro and in vivo, of some triphenylphosphinegold(I) thionucleobases. Metal. Based Drugs,1996, 3, 63-66.
46. Tiekink, E. R. Phosphinegold(I) Thiolates pharmacological use and potential. Bioinorg. Chem. Appl.,2003, 1, 53-67.
47. Crump, D.; Siasios, G.; Tiekink, E. R. A study of the antitumour activity of four triorganophosphinegold(I) thiolates: R3 PAu(SR'), R = Ph, Cy, Et; SR'H = 6-mercaptopurine and R = Et; SR'H = 6-thioguanine. Metal Based Drugs, 1999, 6, 361-368.
48. de vos, D.; Clements, P.; Pyke, S. M.; Smyth, D. R.; Tiekink, E. R. Characterisation and in vitro cytotoxicity of triorganophosphinegold(I) 2-mercaptobenzoate complexes. Metal Based Drugs, 1999, 6, 31-40.
49. Scolaro, C.; Bergamo, A.; Brescacin, L.; Delfino, R.; Cocchietto, M.; Laurenczy, G.; Geldbach, T. J.; Sava, G.; Dyson, P. J. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J. Med. Chem. 2005, 48, 4161-4171.
50. Dorcier, A.; Dyson, P. J.; Gossens, C.; Rothlisberger, U.; Scopelliti, R.; Tavernelli, I. Binding of organometallic ruthenium(II) and osmium(II) complexes to an oligonucleotide: A combined mass spectrometric and theoretical study. Organometallics,2005, 24, 2114-2123.
51. Dorcier, A.; Ang, W. H.; Bolano, S.; Gonsalvi, L.; Juillerat-Jeannerat, L.; Laurenczy, G.; Peruzzini, M.; Phillips, A. D.; Zanobini, F.; Dyson, P. J. In vitro evaluation of rhodium and osmium RAPTA analogues: The case for organometallic anticancer drugs not based on ruthenium. Organometallics, 2006, 25, 4090-4096.
52. Miranda, S.; Vergara, E.; Mohr, F.; de Vos, D.; Cerrada, E.; Mendia, A.; Laguna, M. Synthesis, characterization, and in vitro cytotoxicity of some gold(I) and trans platinum(II) thionate complexes containing water-soluble PTA and DAPTA ligands. X-ray crystal structures of [Au(SC4H3N2)(PTA)], trans-[Pt(SC4H3N2)(2)(PTA)(2)], trans-[Pt(SC5H4N)(2)(PTA)(2)], and trans-[Pt(SC5H4N)(2)(DAPTA)(2)]. Inorg. Chem., 2008, 47, 5641-5648.
53. Vergara, E.; Casini, A.; Sorrentino, F.; Zava, O.; Cerrada, E.; Rigobello, M. P.; Bindoli, A.; Laguna, M.; Dyson, P. J. Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(i) complexes containing hydrophilic phosphine ligands. Chem. Med. Chem., 2010, 5, 96-102.
54. Mirabelli, C. K.; Johnson, R. K.; Sung, C. M.; Faucette, L.; Muirhead, K.; Crooke, S. T. Evaluation of the in vivo antitumor-activity and in vitro cyto-toxic properties of auranofin, a coordinated gold compound, in murine tumor-models. Cancer Res.,1985, 45, 32-39.
55. Simon, T. M.; Kunishima, D. H.; Vibert, G. J.; Lorber, A. Screening trial with the coordinated gold compound auranofin using mouse lymphocytic leukemia P388. Cancer Res., 1981, 41, 94-97.
56. Giraldi, T.; Sava, G.; Perissin, L.; Zorzet, S. Primary tumor-growth and formation of spontaneous lung metastases in mice bearing lewis carcinoma treated with proteinase-inhibitors. Anticancer Res., 1984, 4, 221-224.
57. Stallings-Mann, M.; Jamieson, L.; Regala, R. P.; Weems, C.; Murray, N. R.; Fields, A. P. A novel small-molecule inhibitor of protein kinase C iota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res. 2006, 66, 1767-1774.
58. Todd, R. C.; Lippard, S. J. Inhibition of transcription by platinum antitumor compounds. Metallomics, 2009, 1, 280-291.
59. Bruijnincx, P. C. A.; Sadler, P. J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12, 197-206.
60. Barnard, P. J.; Berners-Price, S. J. Targeting the mitochondrial cell death pathway with gold compounds. Coord. Chem. Rev., 2007, 251, 1889-1902.
61. Rigobello, M. P.; Scutari, G.; Boscolo, R.; Bindoli, A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br. J. Pharmacol., 2002, 136, 1162-1168.
62. Marzano, C.; Gandin, V.; Folda, A.; Scutari, G.; Bindoli, A.; Rigobello, M. P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med., 2007, 42, 872-881.
63. Cox, A. G.; Brown, K. K.; Arner, E. S. J.; Hampton, M. B. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem. Pharmacol., 2008, 76, 1097-1109.
64. Casini, A.; Kelter, G.; Gabbiani, C.; Cinellu, M. A.; Minghetti, G.; Fregona, D.; Fiebig, H. H.; Messori, L. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J. Biol. Inorg. Chem., 2009, 14, 1139-1149.
65. Arner, E. S. J.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem., 2000, 267, 6102-6109.
66. Berggren, M.; Gallegos, A.; Gasdaska, J. R.; Gasdaska, P. Y.; Warnke, J.; Powis, G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res., 1996, 16, 3459-3466.
67. Nakamura, H.; Masutani, H.; Tagaya, Y.; Yamauchi, A.; Inamoto, T.; Nanbu, Y.; Fujii, S.; Ozawa, K.; Yodoi, J. Expression and Growth-promoting effect of adult t-cell leukemia-derived factor a human thioredoxin homolog in hepatocellular-carcinoma. Cancer, 1992, 69, 2091-2097.
68. Powis, G.; Kirkpatrick, D. L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 2007, 7, 392-397.
69. Arner, E. S. J.; Holmgren, A. The thioredoxin system in cancer. Semin. Canc. Biol. 2006, 16, 420-426.
70. Urig, S.; Becker, K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Canc. Biol., 2006, 16, 452-465.
71. Hill, K. E.; McCollum, G. W.; Boeglin, M. E.; Burk, R. F. Thioredoxin reductase activity is decreased by selenium deficiency. Biochem. Biophys. Res. Commun., 1997, 234, 293-295.
72. Gromer, S.; Arscott, L. D.; Williams, C. H.; Schirmer, R. H.; Becker, K. Human placenta thioredoxin reductase isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem., 1998, 273, 20096-20101.
73. Rigobello, M. P.; Scutari, G.; Folda, A.; Bindoli, A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem. Pharmacol. 2004, 67, 689-696.
74. Urig, S.; Fritz-Wolf, K.; Reau, R.; Herold-Mende, C.; Toth, K.; Davioud-Charvet, E.; Becker, K. Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew. Chem., Int. Ed., 2006, 45, 1881-1886.
75. Berners-Price, S. J.; Filipovska, A. The design of gold-based, mitochondria-targeted chemotherapeutics. Aust. J. Chem. 2008, 61, 661-668.
76. Omata, Y.; Folan, M.; Shaw, M.; Messer, R. L.; Lockwood, P. E.; Hobbs, D.; Bouillaguet, S.; Sano, H.; Lewis, J. B.; Wataha, J. C. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1). Toxicol. in Vitro, 2006, 20, 882-890.
77. Rackham, O.; Nichols, S. J.; Leedman, P. J.; Berners-Price, S. J.; Filipovska, A. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: Implications for anticancer therapeutics targeted to mitochondria. Biochem. Pharmacol., 2007, 74, 992-1002.
78. Baker, M. V.; Barnard, P. J.; Berners-Price, S. J.; Brayshaw, S. K.; Hickey, J. L.; Skelton, B. W.; White, A. H. Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and anti-mitochondrial activity. Dalton Trans., 2006, 3708-3715.
79. Hickey, J. L.; Ruhayel, R. A.; Barnard, P. J.; Baker, M. V.; Berners-Price, S. J.; Filipovska, A. Mitochondria-targeted chemotherapeutics: The rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc., 2008, 130, 12570-12571.
80. Witte, A. B.; Anestal, K.; Jerremalm, E.; Ehrsson, H.; Arner, E. S. J. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med., 2005, 39, 696-703.
81. Cenas, N.; Prast, S.; Nivinskas, H.; Sarlauskas, J.; Arner, E. S. J. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J. Biol. Chem., 2006, 281, 5593-5603.
82. Gandin, V.; Fernandes, A. P.; Rigobello, M. P.; Dani, B.; Sorrentino, F.; Tisato, F.; Bĵrnstedt, M.; Bindoli, A.; Sturaro, A.; Rella, R.; Marzano, C. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol., 79, 90-101.
83. Ott, I.; Qian, X. H.; Xu, Y. F.; Vlecken, D. H. W.; Marques, I. J.; Kubutat, D.; Will, J.; Sheldrick, W. S.; Jesse, P.; Prokop, A.; Bagowski, C. P. A gold(i) phosphine complex containing a naphthalimide ligand functions as a trxr inhibiting antiproliferative agent and angiogenesis inhibitor. J. Med. Chem., 2009, 52, 763-770.
84. Sun, R. W. Y.; Che, C. M. The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands. Coord. Chem. Rev., 2009, 253, 1682-1691.
85. Gabbiani, C.; Casini, A.; Messori, L. Gold(III) compounds as anticancer drugs. Gold Bulletin, 2007, 40, 73-81.
86. Sun, R. W. Y.; Ma, D. L.; Wong, E. L. M.; Che, C. M. Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans., 2007, 4884-4892.
87. Che, C. M.; Sun, R. W. Y.; Yu, W. Y.; Ko, C. B.; Zhu, N. Y.; Sun, H. Z. Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem. Communications, 2003, 1718-1719.
88. Wang, Y.; He, Q. Y.; Sun, R. W. Y.; Che, C. M.; Chiu, J. F. Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead. Eur. J. Pharmacol., 2007, 554, 113-122.
89. To, Y. F.; Sun, R. W. Y.; Chen, Y. X.; Chan, V. S. F.; Yu, W. Y.; Tam, P. K. H.; Che, C. M.; Lin, C. L. S. Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int. J. Cancer, 2009, 124, 1971-1979.
90. Lum, C. T.; Yang, Z. F.; Li, H. Y.; Sun, R. W. Y.; Fan, S. T.; Poon, R. T. P.; Lin, M. C. M.; Che, C. M.; Kung, H. F. Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. Int. J. Cancer, 2006, 118, 1527-1538.
91. Tu, S. P.; Sun, R. W. Y.; Lin, M. C. M.; Cui, J. T.; Zou, B.; Gu, Q.; Kung, H. F.; Che, C. M.; Wong, B. C. Y. Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer. Cancer, 2009, 115, 4459-4469.
92. Wang, Y., He, Q.Y., Sun, R.W., Che, C.M., Chiu, J.F. Gold(III) porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxigen species. Cancer Res., 2005, 65, 11553-11564.
93. Chen, L. B. Mitochondrial-membrane potential in living cells. Ann. Rev. Cell Biol., 1988, 4, 155-181.
94. Wang, Y., He, Q.Y., Che, C.M., Tsao, S.W., Sun, R.W., Chiu, J.F. Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways. Biochem. Pharmacol. 2008, 75, 1282-1291.
95. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26, 3279-3290.
96. Autret, A.; Martin, S. J. Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. Mol. Cell., 2009, 36, 355-363.
97. Wang, Y.; He, Q. Y.; Che, C. M.; Chiu, J. F. Proteomic characterization of the cytotoxic mechanism of gold(III) porphyrin 1a, a potential anticancer drug. Proteomics, 2006, 6, 131-142.
98. Chow, K. H.; Sun, R. W. Y.; Lam, J. B. B.; Li, C. K.; Xu, A.; Ma, D. L.; Abagyan, R.; Wang, Y.; Che, C. M. A gold(III) porphyrin complex with antitumor properties targets the Wnt/beta-catenin pathway. Cancer Res., 2010, 70, 329-337.
99. Ronconi, L.; Fregona, D. The Midas touch in cancer chemotherapy: from platinum to gold-dithiocarbamato complexes. Dalton Trans., 2009, 10670-10680.
100. Fregona, D.; Ronconi, L.; Aldinucci, D. Groundbreaking gold(III) anticancer agents. Drug Discov. Today, 2009, 14, 1075-1076.
101. Marzano, C.; Fregona, D.; Baccichetti, F.; Trevisan, A.; Giovagnini, L.; Bordin, F. Cytotoxicity and DNA damage induced by a new platinum(II) complex with pyridine and dithiocarbamate. Chem.-Biol. Interact., 2002, 140, 215-229.
102. Trevisan, A.; Marzano, C.; Cristofori, P.; Venturini, M. B.; Giovagnini, L.; Fregona, D. Synthesis of a palladium(II)-dithiocarbamate complex: biological assay and nephrotoxicity in rats. Arch. Toxicol., 2002, 76, 262-268.
103. Ronconi, L.; Marzano, C.; Zanello, P.; Corsini, M.; Miolo, G.; Macca, C.; Trevisan, A.; Fregona, D. Gold(III) dithiocarbamate derivatives for the treatment of cancer: Solution chemistry, DNA binding, and hemolytic properties. J. Med. Chem. 2006, 49, 1648-1657.
104. Saggioro, D.; Rigobello, M. P.; Paloschi, L.; Folda, A.; Moggach, S. A.; Parsons, S.; Ronconi, L.; Fregona, D.; Bindoli, A. Gold(III) -Dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem. Biol., 2007, 14, 1128-1139.
105. Giovagnini, L.; Ronconi, L.; Aldinucci, D.; Lorenzon, D.; Sitran, S.; Fregona, D. Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes. J. Med. Chem., 2005, 48, 1588-1595.
106. Aldinucci, D.; Lorenzon, D.; Stefani, L.; Giovagnini, L.; Colombatti, A.; Fregona, D. Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. Anti-Cancer Drugs, 2007, 18, 323-332.
107. Aldinucci, D.; Cattaruzza, L.; Lorenzon, D.; Giovagnini, L.; Fregona, D.; Colombatti, A. Antiproliferative and apoptotic effects of two new Pd(II) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. Oncol. Res., 2008, 17, 103-113.
108. Ronconi, L.; Giovagnini, L.; Marzano, C.; Bettio, F.; Graziani, R.; Pilloni, G.; Fregona, D. Gold dithiocarbamate derivatives as potential antineoplastic agents: Design, spectroscopic properties, and in vitro antitumor activity. Inorg. Chem., 2005, 44, 1867-1881.
109. Milacic, V.; Chen, D.; Ronconi, L.; Landis-Piwowar, K. R.; Fregona, D.; Dou, Q. P. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res., 2006, 66, 10478-10486.
110. Milacic, V., Fregona, D., Dou, Q.P. Gold complexes as prospective metal-based anticancer drugs. Histol. Histopathol., 2008, 23, 101-108.
111. Milacic, V.; Dou, Q. P. The tumor proteasome as a novel target for gold(III) complexes: Implications for breast cancer therapy. Coord. Chem. Rev., 2009, 253, 1649-1660.
112. Lopes, U. G.; Erhardt, P.; Yao, R. J.; Cooper, G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem., 1997, 272, 12893-12896.
113. Zhang, X.; Frezza, M.; Milacic, V.; Ronconi, L.; Fan, Y. H.; Bi, C. F.; Fregona, D.; Dou, Q. P. Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes. J. Cell. Biochem., 2010, 109, 162-172.
114. Szweda, P. A.; Friguet, B.; Szweda, L. I. Proteolysis, free radicals, and aging. Free Radic. Biol. Med., 2002, 33, 29-36.
115. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human-tumor cell-lines development of mean graph and compare algorithm. J. Natl. Cancer Inst., 1989, 81, 1088-1092.
116. Boyd, M. R., Paull, K. D., Rubinstein, L. R. In: Cytotoxic anticancer models and concepts for drug discovery and development; Valeriote, F. A., Corbett, T., Backer, L., Ed.; Kluwer Academic Pub.: Amsterdam, 1992, p 11-34.